A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma
Study Identifier:PRISM-1
ClinicalTrials.gov Identifier:NCT06608927
EU CTIS Identifier:2024-513317-12-00
Study Contact Information:
1-888-44-ARCUS or ClinicalTrialInquiry@arcusbio.com
Arcus’ Phase 3 immunotherapy clinical trial for people with metastatic pancreatic ductal adenocarcinoma – PRISM-1 – will be enrolling soon.
Please fill out the form below to receive an email when a trial site near you may be open for enrollment.
Stay Informed About Clinical Trials
Participant Information
I am a...
Fields marked with an asterisk (*) are required.